SEATTLE, BOSTON and TOKYO—Aurion Biotech has appointed Michael Goldstein, MD, MBA, as president and chief medical officer. Dr. Goldstein will lead the company’s clinical strategy, development and operations; medical affairs; and manufacturing and quality teams for its first product candidate, a cell therapy to treat corneal edema secondary to endothelial dysfunction. “As both a world-renowned ophthalmologist and experienced biotech executive with multiple products brought to market under his leadership, Dr. Goldstein is exactly what we need to propel our development at Aurion Biotech,” said Greg Kunst, Aurion Biotech chief executive officer. “We are thrilled to welcome Michael to our team.”

Before joining Aurion Biotech, Dr. Goldstein served as president and chief medical officer of Ocular Therapeutix. Before that, Dr. Goldstein was chief medical officer of Applied Genetic Technologies Corp. Before joining AGTC, Dr. Goldstein held several positions of increasing responsibility with Eleven Biotherapeutics, including chief medical officer and vice president of clinical research.
Since 2002, Dr. Goldstein has served as co-director of the cornea and external disease service and assistant professor of ophthalmology at the New England Eye Center and Tufts University School of Medicine. Previously, he was director of the refractive surgery service and assistant professor of ophthalmology at the University of Florida College of Medicine. Dr. Goldstein has published extensively and is a reviewer for multiple ophthalmology scientific journals.